Pancreatic Cancer Research

ResearcherSoochow UniversityActive in the last 2 years

Jian Zhou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0749-1354; OpenAlex author ID A5046440756. Sources: OpenAlex.

Their work

Papers
19 (first author 2, last author 13)
Trials
0
Grants
0
Labs led
1
Collaborators
42
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: 1 paper · 2019: 3 papers · 2020: none · 2021: 3 papers · 2022: 2 papers · 2023: 2 papers · 2024: none · 2025: none · 2026: 1 paper

Papers 19

  1. SERTAD4-AS1 suppresses pancreatic cancer progression by stabilizing SERTAD4 and inhibiting the Notch1 pathway. Last author DOI 10.1016/j.gendis.2025.101870↗
  2. Long Noncoding RNA LINC00578 Inhibits Ferroptosis in Pancreatic Cancer via Regulating SLC7A11 Ubiquitination. Last author DOI 10.1155/2023/1744102↗
  3. SEMA5A-PLXNB3 Axis Promotes PDAC Liver Metastasis Outgrowth through Enhancing the Warburg Effect. Co-author DOI 10.1155/2023/3274467↗
  4. RhoGDI2 induced malignant phenotypes of pancreatic cancer cells via regulating Snail expression. Co-author DOI 10.1007/s13258-022-01217-0↗
  5. B7H6 Serves as a Negative Prognostic Marker and an Immune Modulator in Human Pancreatic Cancer. Co-author DOI 10.3389/fonc.2022.814312↗
  6. Integrative analysis of TNFRSF6B as a potential therapeutic target for pancreatic cancer. Last author DOI 10.21037/jgo-21-303↗
  7. Development and Validation of a Nomogram Based on Nutritional Indicators and Tumor Markers for Prognosis Prediction of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3389/fonc.2021.682969↗
  8. Signature of gene aberrant alternative splicing events in pancreatic adenocarcinoma prognosis. Last author DOI 10.7150/jca.48661↗
  9. A Panel of Three Biomarkers Identified by iTRAQ for the Early Diagnosis of Pancreatic Cancer. Last author DOI 10.1002/prca.201800195↗
  10. Identification of key genes and pathways downstream of the β-catenin-TCF7L1 complex in pancreatic cancer cells using bioinformatics analysis. First author DOI 10.3892/ol.2019.10444↗
  11. DcR3 promotes proliferation and invasion of pancreatic cancer via a DcR3/STAT1/IRF1 feedback loop. Last author PMID 31911850↗
  12. Identification of potential target genes in pancreatic ductal adenocarcinoma by bioinformatics analysis. Last author DOI 10.3892/ol.2018.8912↗
  13. HIF-2α promotes the formation of vasculogenic mimicry in pancreatic cancer by regulating the binding of Twist1 to the VE-cadherin promoter. Last author DOI 10.18632/oncotarget.17999↗
  14. Methylation of BNIP3 in pancreatic cancer inhibits the induction of mitochondrial-mediated tumor cell apoptosis. Last author DOI 10.18632/oncotarget.18736↗
  15. HIF-2α promotes epithelial-mesenchymal transition through regulating Twist2 binding to the promoter of E-cadherin in pancreatic cancer. Last author DOI 10.1186/s13046-016-0298-y↗
  16. Expression and clinical significance of glucose transporter-1 in pancreatic cancer. Last author DOI 10.3892/ol.2016.4586↗
  17. Decoy receptor 3 suppresses FasL-induced apoptosis via ERK1/2 activation in pancreatic cancer cells. Last author DOI 10.1016/j.bbrc.2015.06.074↗
  18. Expression levels of microRNA-375 in pancreatic cancer. First author DOI 10.3892/br.2013.88↗
  19. MicroRNA-375 is downregulated in pancreatic cancer and inhibits cell proliferation in vitro. Co-author DOI 10.3727/096504013x13589503482734↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuchen Tang · 7 shared papers, 2018–2026 · strength 1.09
  2. Dechun Li · 11 shared papers, 2012–2022 · strength 0.89
  3. Haoran Li · 4 shared papers, 2021–2026 · strength 0.72
  4. Bin Yi · 4 shared papers, 2021–2026 · strength 0.67
  5. Yijun Wei · 4 shared papers, 2019–2026 · strength 0.64
  6. Dongming Zhu · 7 shared papers, 2012–2023 · strength 0.58
  7. Dongming Zhu · 6 shared papers, 2015–2022 · strength 0.56
  8. Jian Yang · 6 shared papers, 2016–2022 · strength 0.52
  9. Jian Yang · 3 shared papers, 2019–2026 · strength 0.48
  10. Zixiang Zhang · 4 shared papers, 2018–2022 · strength 0.46
  11. Yi Zhang · 5 shared papers, 2015–2022 · strength 0.39
  12. Jian Yang · 2 shared papers, 2023 · strength 0.36
  13. Jun Yao · 3 shared papers, 2019–2022 · strength 0.36
  14. Jun Yao · 1 shared paper, 2026 · strength 0.29
  15. Yujie Huang · 2 shared papers, 2021–2022 · strength 0.26
  16. Ye Li · 3 shared papers, 2016–2021 · strength 0.25
  17. Zixiang Zhang · 4 shared papers, 2012–2019 · strength 0.24
  18. Zixiang Zhang · 1 shared paper, 2023 · strength 0.18
  19. Kun Wang · 1 shared paper, 2023 · strength 0.18
  20. Jun Yao · 1 shared paper, 2023 · strength 0.18
  21. Qiuhua Liu · 1 shared paper, 2022 · strength 0.13
  22. Chen Zhang · 1 shared paper, 2021 · strength 0.13
  23. Shiduo Song · 3 shared papers, 2012–2015 · strength 0.13
  24. Peng Du · 1 shared paper, 2021 · strength 0.12
  25. Xin Zhao · 1 shared paper, 2022 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.